Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release


Posted on: 07 Oct 16

Mechelen, Belgium, 7 October 2016 - Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three studies on the performance of its Idylla(TM) based molecular diagnostic tests will be presented at the renowned annual conference of the European Society for Medical Oncology (ESMO), to be held from 7-11 October 2016 in Copenhagen (Denmark).

The ESMO conference is a major scientific oncology conference, attracting an international community of experts across various disciplines, all focused on finding the most effective cancer treatment solutions available today. With approximately 20,000 attendees from all over the world, it offers a key platform for academic groups and companies to present their latest advances in oncology research.

Below is a summary of the performance studies presented at ESMO for three different Idylla(TM) tests:

  • AstraZeneca KRAS Comparison Study[1]: concerns a comparison study[2] organised by AstraZeneca, a global biopharmaceutical company, which assessed KRAS mutation detection and functional characteristics such as time-to-result and sensitivity across 12 different KRAS diagnostics technologies commonly used in clinical practice, including the Idylla(TM) KRAS Mutation Test[3].
  • Idylla(TM) NRAS-BRAF-EGFRS492R Mutation Assay Comparison Study[4]: discloses results of a comparison of the Idylla(TM) NRAS-BRAF-EGFRS492R Mutation Assay[5] with routine sequencing technologies at five European centers.
  • Idylla(TM) EGFR Mutation Assay Performance Study[6]: concerns a study on the Idylla(TM) EGFR Mutation Assay (Research Use Only), assessed on so-called cell line derived materials[7] and on formalin-fixed paraffin-embedded (FFPE) tissue slices from 141 non-small-cell lung cancer samples.

Biocartis can be visited at booth number 428 at ESMO.

Editor's Details

Mike Wood

Last updated on: 07/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.